

SNBTS DOCUMENT REQUEST No:

2011/00121a**Penrose Inquiry****RESPONSE TO REQUEST BELOW****John Cash**

**From:** Lovell G (Gemma) [mailto: [REDACTED]]  
**Sent:** 28 November 2011 14:57  
**To:** Murray Susan (NATIONAL SERVICES SCOTLAND)  
**Cc:** McElroy Kathryn (NATIONAL SERVICES SCOTLAND); Turnbull Tracey (NATIONAL SERVICES SCOTLAND); Tullis D (Douglas)  
**Subject:** Questions for Dr Foster and Professor Cash in relation to product inserts

Dear Susan

I refer to Dr Perry's draft statement, received by the Inquiry on 10 November 2011 (2011/00121). Amongst other questions, the Inquiry asked Dr Perry:

(2) What discussions were there amongst the staff of the PFC of the possibility of including reference to the risk of HIV transmission on package inserts included with their factor concentrates between 1982 and 1985?

As part of his response to Question 2, Dr Perry states:

*"I cannot recall whether or not in 1984 (following my appointment as Director) I discussed with others in PFC or elsewhere the possibility or desirability of modifying our 'warnings' to include AIDS. I think it is possible that such discussions took place with eg Dr Cash, Dr Boulton and the Haemophilia Directors. For example, Dr Foster has advised me that he recalls that in late 1983 the SNBTS (Professor Cash) suggested, at a meeting between SNBTS and Haemophilia Directors, the inclusion of an AIDS warning but that this suggestion was rejected by those present in the belief that such action might cause patients unnecessary anxiety. However the SNBTS has been unable to find any record of this".*

I would be grateful if you could ask Dr Foster and Professor Cash if they have any recollection of this meeting or the events surrounding it.

Kind regards,

**Gemma Lovell**

**Response: I share the recollections of Dr Perry and Dr Foster but am not aware of documents which confirm this. I seem to recall that it arose at the time (early 1980s) when I was a little concerned at the dearth of the reporting of adverse**

reactions by Haemophilia Centre staff. That said, I recall, much later, following one of my visits to Australia, I proposed that we ought to consider including in the information on our blood/blood component labels a hepatitis risk warning. This proposal did not enjoy much support from colleagues and in due course a legal opinion was sought by Jim Donald (CSA General Manager)– a copy of which and associated correspondence should exist in the Inquiry's database. The outcome was 'no change': no hepatitis warning risk was added to our blood/component labels

John Cash  
December 2011